KIP2 Antibody

What is p57 Kip2 and what is its primary function in cellular processes?

p57 Kip2 (Cyclin-dependent kinase inhibitor 1C) is a 57 kDa protein that functions primarily as a tumor suppressor and negative regulator of cell proliferation. It acts as a potent tight-binding inhibitor of several G1 cyclin/Cdk complexes, specifically targeting multiple G1 cyclin/Cdk complexes to restrict cell cycle progression . This regulation is vital for maintaining proper cell division and preventing uncontrolled proliferation that can lead to tumorigenesis. Unlike other members of the p21 Waf1/Cip1 family, p57 Kip2 functions independently of p53 in the cell cycle control mechanism, adding another layer of complexity to its regulatory role .

What applications are p57 Kip2 antibodies commonly used for in research settings?

p57 Kip2 antibodies are utilized in multiple research applications, including:

• Western blotting (WB) - typically at 1:1000 dilution

• Immunoprecipitation (IP) - typically at 1:50 dilution

• Immunofluorescence (IF) - typically at 1:100 dilution

• Immunohistochemistry (IHC)

• Enzyme-linked immunosorbent assay (ELISA)

One of the most significant clinical research applications is in the identification and differentiation of complete hydatidiform mole (CHM) from partial hydatidiform mole (PHM). In CHM, there is no nuclear labeling of cytotrophoblasts and stromal cells, while in PHM, both cytotrophoblasts and stromal cells stain positive for p57 Kip2 . This distinction is clinically relevant as complete moles carry a high risk of persistent disease and choriocarcinoma, while partial moles have a very low risk .

What species reactivity is available for common p57 Kip2 antibodies?

Different p57 Kip2 antibodies offer varying species reactivity profiles:

When selecting an antibody for research, it's essential to verify species cross-reactivity to ensure compatibility with your experimental model system .

How should p57 Kip2 antibodies be stored and handled for optimal performance?

While the search results don't provide specific storage conditions for all antibodies, general antibody handling principles apply. Most antibodies are stored at either 4°C for short-term use or at -20°C for long-term storage. Repeated freeze-thaw cycles should be avoided as they can compromise antibody performance. For diluted working solutions, the addition of stabilizing proteins (such as BSA) and antimicrobial agents is typically recommended. Always refer to the manufacturer's specific storage recommendations for the particular antibody you are using .

How does p57 Kip2 interact with other cellular proteins to regulate diverse cellular functions?

Beyond its canonical role as a CDK inhibitor, p57 Kip2 engages in several protein-protein interactions that expand its functionality:

• Interaction with LIMK-1: The unique central region of p57 Kip2 interacts with LIMK-1, a downstream effector of the Rho family of GTPases. By sequestering LIMK-1 in the nucleus, p57 Kip2 disrupts actin dynamics within cells, which may be linked to its essential role in embryonic development .

• JNK/SAPK inhibition: The carboxyl-terminal QT domain of p57 Kip2 binds to and inhibits JNK/SAPK activity, thus regulating cellular apoptosis and differentiation processes .

These interactions highlight p57 Kip2's multifunctional nature beyond simple cell cycle regulation, positioning it as a central node in multiple cellular regulatory networks controlling development, differentiation, and cytoskeletal organization.

What are the mechanisms regulating p57 Kip2 protein expression and stability?

The expression and stability of p57 Kip2 are tightly regulated through several mechanisms:

• Restricted tissue expression: Expression levels of human p57 Kip2 are more restricted than other CDK inhibitors, suggesting tissue-specific regulatory mechanisms .

• Post-translational modification: p57 Kip2 stability is controlled through ubiquitination and subsequent degradation via the Skp1/Cul1/F-box-type E3 ubiquitin ligase complex SCF-Skp2. This degradation pathway is dependent on phosphorylation at Thr310 .

• Phosphorylation-dependent regulation: Similar to the related protein p27 Kip1, where phosphorylation at Thr187 regulates protein stability, phosphorylation plays a crucial role in determining p57 Kip2 half-life and activity .

Understanding these regulatory mechanisms is essential for interpreting experimental results and developing strategies to modulate p57 Kip2 activity in research and potential therapeutic applications.

What are the key technical considerations when using p57 Kip2 antibodies for differentiating complete and partial hydatidiform moles?

The use of p57 Kip2 antibodies for molar pregnancy diagnosis requires careful attention to several technical aspects:

• Internal controls: Intervillous trophoblastic islands (IVTIs) demonstrate nuclear labeling in all three entities (complete mole, partial mole, and hydropic abortus) and should be used as internal controls to validate staining procedures .

• Staining pattern interpretation: In normal placenta and PHM, many cytotrophoblast nuclei and stromal cells are labeled with p57 Kip2 antibody. The absence of this labeling pattern in cytotrophoblasts and stromal cells is indicative of CHM .

• Limitations of ploidy studies: While most complete hydatidiform moles are diploid and most partial moles are triploid, ploidy studies alone will identify partial moles but will not differentiate complete moles from non-molar gestations. p57 Kip2 immunostaining provides this critical distinction .

• Antibody selection: For this diagnostic application, antibodies with demonstrated specificity are crucial. For instance, antibodies like KP10 and 57P06 have been validated for this purpose and show no cross-reaction with related proteins like p27 Kip1 .

The accurate interpretation of p57 Kip2 immunostaining in these contexts requires expertise in placental pathology and familiarity with the expected staining patterns.

How can researchers optimize p57 Kip2 antibody performance in different experimental applications?

Optimization strategies differ based on the specific application:

• Western Blotting (1:1000 dilution):

  • Ensure complete protein transfer by optimizing transfer conditions

  • Use appropriate blocking agents to reduce background

  • Consider using reducing conditions to expose epitopes

  • Validate specificity by positive and negative controls

• Immunoprecipitation (1:50 dilution):

  • Pre-clear lysates to reduce non-specific binding

  • Use appropriate bead systems (protein A/G or specific IgG-binding resins)

  • Optimize washing conditions to maintain specific interactions while reducing background

• Immunofluorescence (1:100 dilution):

  • Optimize fixation methods (paraformaldehyde, methanol, or acetone) based on epitope sensitivity

  • Consider antigen retrieval methods if necessary

  • Use appropriate permeabilization reagents for intracellular targets

  • Include controls for autofluorescence and non-specific binding

The availability of p57 Kip2 antibodies conjugated to various fluorophores (CF®405S, CF®488A, CF®568, CF®594, CF®640R, CF®647) enables multiplexed imaging studies .

What are the known associations between p57 Kip2 mutations and human diseases?

Mutations in p57 Kip2 have been implicated in several human pathologies:

• Beckwith–Wiedemann syndrome (BWS): This genetic disorder is characterized by an increased risk of childhood cancer. Mutations or epigenetic alterations affecting p57 Kip2 expression are associated with this syndrome .

• Human malignancies: Various cancers show altered p57 Kip2 expression or function, consistent with its role as a tumor suppressor .

• Gestational trophoblastic disease: The absence of p57 Kip2 expression in complete hydatidiform moles reflects the underlying genetic abnormality in these lesions and correlates with their increased risk of progressing to persistent gestational trophoblastic disease or choriocarcinoma .

Understanding these disease associations not only illuminates the biological significance of p57 Kip2 but also underscores its potential as a diagnostic marker and therapeutic target.

What control samples should be included when performing p57 Kip2 immunohistochemistry in diagnostic applications?

When performing p57 Kip2 immunohistochemistry for diagnostic purposes, particularly in the context of molar pregnancies, the following controls are essential:

• Positive tissue controls: Normal placental tissue samples where cytotrophoblast nuclei and stromal cells show positive nuclear labeling .

• Internal positive controls: Intervillous trophoblastic islands (IVTIs) which demonstrate nuclear labeling across all placental pathologies (normal, CHM, PHM) and serve as built-in controls for staining efficacy .

• Negative controls: Samples processed identically but with primary antibody omitted to assess non-specific binding of secondary detection systems.

• Known CHM samples: Previously confirmed cases of complete hydatidiform mole showing characteristic absence of nuclear labeling in cytotrophoblasts and stromal cells .

Proper controls ensure diagnostic accuracy and help troubleshoot technical issues that may affect interpretation.

What antibody conjugates are available for p57 Kip2 detection in multiparameter studies?

Various conjugated forms of p57 Kip2 antibodies are available for different experimental approaches:

These conjugates enable flexible experimental design, particularly for multiparameter studies requiring simultaneous detection of multiple targets. When selecting fluorescent conjugates, researchers should consider spectral compatibility with other fluorophores in multiplexed experiments and the relative brightness of different dyes .

How can researchers troubleshoot specificity issues with p57 Kip2 antibodies?

When encountering specificity concerns with p57 Kip2 antibodies, consider the following troubleshooting approaches:

• Verify antibody clone and source: Different clones may recognize different epitopes with varying specificity. For instance, antibody KP39 is known to detect p57 Kip2 protein across mouse, rat, and human samples , while other antibodies may have more restricted species reactivity.

• Perform blocking experiments: Pre-incubate the antibody with purified p57 Kip2 protein or immunizing peptide to confirm specificity.

• Use genetic controls: Tissues or cells with known knockdown/knockout of p57 Kip2 can serve as negative controls.

• Cross-validate with multiple antibodies: Using antibodies that recognize different epitopes can help confirm specificity. For example, the search results mention antibodies KP39, KP10, and 57P06, which could potentially recognize different regions of the protein .

• Western blot validation: Confirm that the antibody detects a single band of the expected molecular weight (57 kDa) in your experimental system .

How is p57 Kip2 being utilized in cancer research beyond its role as a tumor suppressor?

Current cancer research is exploring p57 Kip2 in several innovative directions:

• Biomarker development: The differential expression of p57 Kip2 in various cancer types is being investigated for its potential as a prognostic or predictive biomarker .

• Therapeutic target identification: Understanding the mechanisms by which p57 Kip2 regulates cell proliferation and interacts with other signaling pathways is revealing potential nodes for therapeutic intervention .

• Cell cycle checkpoint studies: As a key regulator of G1 phase arrest, p57 Kip2 is central to research on cell cycle checkpoint dysregulation in cancer .

• Epigenetic regulation: Studies on the epigenetic control of p57 Kip2 expression are providing insights into cancer development mechanisms and potential epigenetic therapies .

These research directions highlight the multifaceted relevance of p57 Kip2 in cancer biology and therapeutic development beyond its classical characterization as a tumor suppressor.

What are the emerging roles of p57 Kip2 in developmental biology and stem cell research?

Recent research has uncovered several non-canonical functions of p57 Kip2 in development and stem cell biology:

• Embryonic development regulation: The interaction between p57 Kip2 and LIMK-1 affects actin dynamics, which appears to be essential for proper embryonic development .

• Stem cell differentiation control: Through its ability to arrest cells in G1 phase, p57 Kip2 plays a crucial role in the differentiation decisions of various stem cell populations .

• Tissue-specific development: The restricted expression pattern of p57 Kip2 compared to other CDK inhibitors suggests specialized roles in the development of specific tissues and organs .

• Cellular stress responses: p57 Kip2's role in cellular responses to growth signals and stress positions it as a key regulator of developmental adaptations to changing environments .

These developmental roles explain why p57 Kip2 dysfunction can lead to developmental disorders like Beckwith-Wiedemann syndrome and highlight its potential importance in regenerative medicine applications.

What technological developments are enhancing the utility of p57 Kip2 antibodies in research?

Several technological advances are expanding the applications of p57 Kip2 antibodies:

• Advanced fluorophore conjugations: The availability of p57 Kip2 antibodies conjugated to high-performance fluorophores like the CF® dye series enables more sensitive detection and multiplexed imaging approaches .

• Proximity ligation assays: These techniques allow for the in situ detection of protein-protein interactions involving p57 Kip2, providing spatial information about its interactions with partners like LIMK-1 and components of the cell cycle machinery.

• Single-cell analysis techniques: Integration of p57 Kip2 antibodies into single-cell proteomics workflows enables investigation of its expression and function at unprecedented resolution.

• Automated image analysis: Machine learning algorithms are being developed to standardize the interpretation of p57 Kip2 immunostaining in diagnostic applications, potentially improving consistency and accuracy.

These technological developments are enabling researchers to address increasingly sophisticated questions about p57 Kip2 biology and pathology.

What considerations should researchers keep in mind when selecting between different p57 Kip2 antibody clones?

When choosing between different p57 Kip2 antibody clones (such as KP39, KP10, 57P06), researchers should consider:

• Epitope specificity: Different clones recognize different epitopes, which may be differentially accessible depending on protein conformation, post-translational modifications, or interaction partners .

• Cross-reactivity profiles: Some antibodies are explicitly tested for lack of cross-reactivity with related proteins. For example, both KP10 and 57P06 are noted to show no cross-reaction with p27 Kip1 .

• Validated applications: Certain clones may be better validated for specific applications. For instance, clone KP39 is validated for Western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, and ELISA .

• Species reactivity: Antibodies vary in their cross-species reactivity. KP39 recognizes p57 Kip2 from mouse, rat, and human origins , while others may have more limited species reactivity.

• Conjugation options: If specific conjugates are required for your application, verify their availability for your antibody of interest. KP39, for example, is available with various conjugates including HRP, FITC, PE, and Alexa Fluor® .